Well Health Technologies Corp. · TSX:WELL
Well Health Technologies — Q2 2026 Earnings Presentation
27 slides from Well Health Technologies's earnings presentation, Aug 6, 2026
Slide 1: Q2 - 2026 Earnings Presentation
Q2 - 2026 Earnings Presentation August 6, 2026
Slide 2: Disclaimer
Disclaimer This presentation contains forward - looking statements and forward - looking information within the meaning of applicable securitie s laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forw ard - looking st
Slide 3: Execution Across Every Pillar of Our Strategy
Execution Across Every Pillar of Our Strategy Clinic transactions with corresponding revenue and billable provider metrics HIGHLIGHTS: 1. WELL Canada achieved $100M Adjusted EBITDA target New 2026 Guidance1: 2. Completed $150M bond offering $1.58-1.65B Revenue $185-195M Adj. EBITDA 3. WELLSTAR compl
Slide 4: WELL Q2-2026 Key Financial Highlights
WELL Q2-2026 Key Financial Highlights1 Q2 Revenue Q2 Adj. EBITDA Q2 Adj. Sh. EBITDA $400.4M $48.1M $35.3M +12% Y/Y -3% Y/Y -6% Y/Y +102% Y/Y Q2 Normalized Revenue Q2 Normalized Adj. EBITDA Q2 Normalized Adj. EBITDA $395.6M $43.3M $32.0M +14% Y/Y +8% Y/Y +4% Y/Y 1) All figures include $4.8 million in
Slide 5: WELL Q2-2026 Key Financial Highlights
WELL Q2-2026 Key Financial Highlights1 Q2 Adj. Gross Profit Q2 Adj. Gross Margin Q2 Adj. Net Income $178.4M 44.6% $11.6M +12% Y/Y +10 bps Y/Y -55% Y/Y +102% Y/Y Q2 Normalized Adj. Gross Q2 Normalized Adj. Gross Q2 Normalized Adj. Net Profit Margin Income $173.6M 43.9% $9.2M +17% Y/Y +90 bps Y/Y -56%
Slide 6: WELL June-2026 – Monthly Performance Exiting Quarter
WELL June-2026 – Monthly Performance Exiting Quarter1 June 2026 Revenue June 2026 Adj. EBITDA June 2026 Adj. Sh. EBITDA $144.3M $17.6M $13.3M +24% Y/Y +12% Y/Y +28% +102%Y/Y Y/Y June 2026 Normalized June 2026 Normalized Adj. June 2026 Normalized Adj. Sh. Revenue EBITDA EBITDA $144.2M $17.6M $13.2M +
Slide 7: WELL Q2-2026 Operational Highlights
WELL Q2-2026 Operational Highlights1 5,000+ 2.0M+ 1.4M Providers in WELL's Clinic CAN patient visits Patient visits (CAN + US) Network in Q2-2026 +19% YoY (1,500+ physicians in Canada) (5.6M annualized run-rate) (+5% organic) 45,000+ 3.1 M+ +28% Unique Providers supported Total Care Interactions2 Yo
Slide 8: Making a Positive Impact on Canadian Healthcare
Making a Positive Impact on Canadian Healthcare 2-Week 80% 85K+ Wait Time Reduction in No-Shows WELL Trust Consents WELL Cardiologists vs. 15.3-week at WELL Clinics due to tech enablement collected as of June 30, 2026 industry average1 1) Fraser Institute, Waiting Your Turn: Wait Times for Health Ca
Slide 9: Strengthening Our Executive Leadership Team
Strengthening Our Executive Leadership Team Four strategic appointments across operations, legal, technology and public sector strengthen WELL's leadership bench Derek Clark Loreto Grimaldi Kaytek Przybylski Dr. Andrew Bond Chief Operating Officer Chief Legal Officer Chief Digital & Information Chie
Slide 10: Six Defining Pressures the Canadian Healthcare System is Facing Today
Six Defining Pressures the Canadian Healthcare System is Facing Today Access Provider burnout 3 Chronic disease & acute 1 2 6.5M Canadians have no 47% of physicians report capacity family doctor. burnout. 20% of hospital budgets ($2.5B) tied to avoidable acute-care use.1 4 Fiscal ceiling 5 Aging pop
Slide 11: WELL's Vision: Operating System Underpinning Outpatient Healthcare
WELL’s Vision -> To be the Operating System Underpinning Outpatient Healthcare at Scale for a More Modern Canadian Healthcare System Delivery Technology Intelligence WELL’s Clinics, EMR, billing & AI & analytics turn WELL Diagnostics & connectivity Canada’s largest virtual care deliver software run
Slide 12: OneWELL
OneWELL One integrated platform to address Canada’s healthcare needs . 01 02 03 Delivering Tech-enabling Population Health & AI connected care Providers 12
Slide 13: Successful Inaugural Bond Offering
Successful Inaugural Bond Offering Extends debt maturity to 2031 and strengthens the balance sheet to support continued growth in Canada . $150M 6.875% 2031 July 15, 2026 Closed July 15 Senior Unsecured Coupon (per annum) Maturity (5-year Notes) Closed USE OF PROCEEDS TRANSACTION HIGHLIGHTS ✓ WELL's
Slide 14: WELL Canada Experiencing Consistent Growth & Profitability
WELL Canada Experiencing Consistent Growth & Profitability WELL Canada WELL Canada Q2 Revenue Growth Q2 Adj. EBITDA Growth (C$ in 000s) (C$ in 000s) 200,000 30,000 One - time One - time 2 176,607 27,354 180,000 Reimbursement lift Reimbursement lift 2 160,000 25,000 22,983 140,000 134,346 20,000 120,
Slide 15: WELL Canadian Clinics Financial Performance
WELL Canadian Clinics Financial Performance WELL Canadian Clinics WELL Canadian Clinics WELL Canadian Clinics Count1 Annual Revenue Growth Annual Adj. EBITDA Growth (C$ in 000s) (C$ in 000s) 300 500,000 275 70,000 450,000 250 60,000 400,000 350,000 50,000 200 300,000 40,000 150 250,000 128 30,000 20
Slide 16: WELL Providers Are Seeing More Patients
WELL Providers Are Seeing More Patients WELL Canadian Clinics Billable Providers in WELL’s Patient Visits / Billable Provider1 Patient Visits Canadian Clinics Network 1,600,000 3,000 700 1,400,000 1,361,952 2,444 600 576 2,500 548 1,200,000 500 1,061,058 1,935 449 2,000 1,000,000 1,706 400 800,000 7
Slide 17: Canadian Clinic Recent M&A Activity
Canadian Clinic Recent M&A Activity Clinic transactions with corresponding revenue and billable provider metrics Q3-2025 Q4-2025 Q1-20261 Q2-2026 +5 Clinics +25 Clinics +3 Clinics +23 Clinics 5 transactions 7 transactions 3 transactions 3 transactions +$27.5M +$45.6M +$34.0M +$67.8M Annual Revenue A
Slide 18: WELL Canada M&A Pipeline
WELL Canada M&A Pipeline WELL continues to execute on a robust pipeline, driving growth and sustaining strong operational momentum. $340 million+ Revenue WELL Canada 30+ Targets Engaged Total Pipeline(1) 70+ Clinics WELL Canada ~$193 million Revenue Under LOI or Advanced Stage(2) 5 Signed LOIs 1) WE
Slide 19: WELLSTAR: TSXV Listing & $50M Concurrent Financing
WELLSTAR: TSXV Listing & $50M Concurrent Financing Concurrent Financing closed July 30, 2026 ahead of WELLSTAR’s planned standalone TSXV listing $50M ~$95M Rule of 40+ $162M Gross Proceeds Expected 2026 Growth + Profitability Total Raised Last 19 Revenue Months1 TRANSACTION HIGHLIGHTS “A standalone
Slide 20: WELLSTAR: Continued Financial Out-performance
WELLSTAR: Continued Financial Out-performance Revenue1 Annual Recurring Revenue (ARR) Adj. EBITDA2 (C$ in 000s) (C$ in 000s) (C$ in 000s) 90,000 Pre - Pubco 25,000 7,000 23,031 Costs 4 +37% 80,109 80,000 +37% +32% 6,000 5,808 20,000 193 70,000 +58% 16,811 58,436 5,000 +27% 60,000 +45% 4,414 15,000 5
Slide 21: Strategic Alternatives Processes for US Assets
Strategic Alternatives Processes for US Assets 21
Slide 22: Q2-2026 Financial Highlights: Revenue
Q2-2026 Financial Highlights: Revenue (C$ in 000,000s) 450 4.8 400.4 400 6.1 395.6 51.2 356.7 350 347.0 -9.7 -8.7 300 250 200 2 Q2-25 CM Net Deferral… Q2-25 One Time… 1 US Patient Services & Others Q2-26 CM Net Deferral… Q2-25 Impact Normalized Q2-25 Reimbursement 3 WELL Canada Normalized Q2-26 Impa
Slide 23: Q2-2026 Financial Highlights: Adjusted EBITDA
Q2-2026 Financial Highlights: Adjusted EBITDA (C$ in 000,000s) 60 50 49.7 2.8 4.8 48.1 9.8 43.3 40.1 -4.0 40 -9.7 -5.4 30 20 10 0 1 2 3 Increase Decrease Total 1) WELL Canada includes Canadian Clinics, WELLSTAR and CYBERWELL 2) Others includes Corporate, WELL Research, and HEALWELL 3) One time reimb
Slide 24: Q2-2026 Financial Highlights: Adjusted Net Income
Q2-2026 Financial Highlights: Adjusted Net Income2 (C$ in 000,000s) 30 25.8 25 20.9 20 -4.9 -3.8 15 2.4 11.6 10 3.5 0.6 9.2 -8.2 5 -3.9 0 4 1 3 Increase Decrease Total (1) Non-operating Items include other items such as Depreciation, FX gain/loss, Interest Income, Gain on disposal of assets and inve
Slide 25: Q2-2026 Financial Highlights: Adjusted FCFA2S
Q2-2026 Financial Highlights: Adjusted FCFA2S Adjusted Free Cashflow Attributable to Shareholders (C$ in 000,000s) 14 3.3 12 11.7 3.8 11.7 -1.0 10 -2.5 8 -3.6 6 4 2 0 1 1 Q2 - 25 Corporate/WELL Research Cash taxes Cash interest Capex Net growth Q2 - 26 Increase Decrease Total (1) Values refer to cha
Slide 26: Upgraded Outlook
Upgraded Outlook Disciplined Capital Allocation Program Driving Scale 2026 Guidance1: WELL Canada2 $1.58-1.65B Revenue >$1 Billion Revenue $185-195M Adj. EBITDA run-rate in 18-months WELLSTAR expected to WELL Canadian Clinics begin trading on TSX >$100M Adj. EBITDA Venture Exchange in run-rate by en
Slide 27: Contact
Contact Hamed Shahbazi CEO, Chairman & Founder hamed@well.company Eva Fong Chief Financial Officer eva.fong@well.company Pardeep Sangha Investor Relations investor@well.company www.well.company Vancouver, BC Canada 27 27
WELL Health Technologies — Q2 2026 Earnings Presentation on 6ix